David Westerman

Identification errors in medical research: privacy at all costs?

James A Rickard, Toni-Maree Rogers, David A Westerman, Cathy Carolan, Stephen B Fox

Journal article  |  2023  |  Pathology

A novel ATRX variant with splicing consequences in myelodysplastic syndrome with acquired alpha thalassaemia.

Phillip C Nguyen, Ing Soo Tiong, David A Westerman, Piers Blombery

Journal article  |  2023  |  Br J Haematol

Utility of High-Throughput Sequencing of Immunoglobulin Genes for MRD in Lymphoid Malignancy in the Context of Current Immunotherapeutics

Imogen R Caldwell, Michael Ingbritsen, Yan Zhuang Yap, Mark R Dowling, Ing S Tiong, David A Westerman, Piers Blombery

Journal article  |  2022  |  Blood

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

Adrian Minson, Nada Hamad, Chan Y Cheah, Constantine S Tam, Piers Blombery, David A Westerman, Stephen Lade, David Ritchie, Rachel M Koldej, Mary Ann Anderson, Amit Khot, John F Seymour, Molly Robertson, Imogen R Caldwell, Georgina L Ryland, Jing Xie, Huw Morgan, Michael Dickinson

Journal article  |  2022  |  Blood

Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy

Rithin Nedumannil, David Ritchie, Ashish Bajel, Ashley P Ng, Simon J Harrison, David Westerman

Journal article  |  2022  |  EUROPEAN JOURNAL OF HAEMATOLOGY

Multi-parametric flow cytometry (MFC) has a well-established role in measurable residual disease (MRD) monitoring in patients with..

Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review

Martin Vu, Koen Degeling, Ella R Thompson, Piers Blombery, David Westerman, Maarten J IJzerman

Journal article  |  2022  |  EUROPEAN JOURNAL OF HAEMATOLOGY

OBJECTIVES: Molecular biomarker tests can inform the clinical management of genomic heterogeneous hematological malignancies, yet ..

Unsupervised computational detection of measurable residual disease in chronic lymphocytic leukaemia

Phillip C Nguyen, Vuong Nguyen, Neil Came, David A Westerman

Journal article  |  2022  |  Pathology

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL

Piers Blombery, Thomas E Lew, Michael A Dengler, Ella R Thompson, Victor S Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka M Handunnetti, Dennis A Carney, David A Westerman, Constantine S Tam, Jerry M Adams, Andrew H Wei, David CS Huang, John F Seymour, Andrew W Roberts, Mary Ann Anderson

Journal article  |  2022  |  BLOOD

The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (..

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

Ella R Thompson, Tamia Nguyen, Yamuna Kankanige, John F Markham, Mary Ann Anderson, Sasanka M Handunnetti, Rachel Thijssen, Paul Sung-Hao Yeh, Constantine S Tam, John F Seymour, Andrew W Roberts, David A Westerman, Piers Blombery

Journal article  |  2022  |  BLOOD ADVANCES

The genomic landscape of resistance to targeted agents (TAs) used as monotherapy in chronic lymphocytic leukemia (CLL) is complex ..

P776: A PHASE 2, OPEN-LABEL, ASCENDING DOSE STUDY OF KER-050 FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES

S Tan, A Arbelaez, L Chee, CY Fong, D Hiwase, G Kannourakis, J Kwan, J Liang, A Puliyayil, H Rose, D Ross, T-C Teh, D Westerman, J Wight, W Feng, J Lachey, A McGinty, H Natarajan, C Rovaldi, S Cooper

Journal article  |  2022  |  HemaSphere